Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew W Davis

Showing results (1-10 of 36) with videos related to

Pageof 4
Sort By:
Cutis|March 13, 2003
Study design and selection criteria in the BEST studyToivo Rist, Matthew W Davis
Cutis|March 13, 2003
The BEST study: results according to prior treatmentDavid Rodriguez, Matthew W Davis
Clinical Drug Investigation|January 24, 2014
Effect of steady-state atorvastatin on the pharmacokinetics of a single dose of colchicine in healthy adults under fasted conditionsMatthew W Davis, Suman Wason
Cutis|March 13, 2003
The BEST study: evaluating efficacy by selected demographic subsetsAdolfo Fernandez-Obregon, Matthew W Davis
Journal of Clinical Pharmacology|February 8, 2002
Comparison of the pharmacokinetics of oxycodone administered in three Percocet formulationsArnold R Gammaitoni, Matthew W Davis
The Annals of Pharmacotherapy|February 19, 2002
Pharmacokinetics and tolerability of lidocaine patch 5% with extended dosingArnold R Gammaitoni, Matthew W Davis
Cutis|March 13, 2003
Improving patient satisfaction and acne severity in patients with mild to moderate acne: the BEST studyJonathan Weiss, Joel Shavin, Matthew W Davis
Cutis|March 13, 2003
Overall results of the BEST study following treatment of patients with mild to moderate acneJonathan Weiss, Joel Shavin, Matthew W Davis
The Consultant Pharmacist : the Journal of the American Society of Consultant Pharmacists|March 7, 2013
Colchicine-antimicrobial drug interactions: what pharmacists need to know in treating goutMatthew W Davis, Suman Wason, Jennifer L Digiacinto
Clinical Therapeutics|June 28, 2011
Single-dose bioequivalence of 105-mg fenofibric acid tablets versus 145-mg fenofibrate tablets under fasting and fed conditions: a report of two phase I, open-label, single-dose, randomized, crossover clinical trialsAnthony R Godfrey, Jennifer Digiacinto, Matthew W Davis
Pageof 4

Showing results (1-10 of 36) with videos related to

Sort By:
Pageof 4
Cutis|March 13, 2003
Study design and selection criteria in the BEST studyToivo Rist, Matthew W Davis
Cutis|March 13, 2003
The BEST study: results according to prior treatmentDavid Rodriguez, Matthew W Davis
Clinical Drug Investigation|January 24, 2014
Effect of steady-state atorvastatin on the pharmacokinetics of a single dose of colchicine in healthy adults under fasted conditionsMatthew W Davis, Suman Wason
Cutis|March 13, 2003
The BEST study: evaluating efficacy by selected demographic subsetsAdolfo Fernandez-Obregon, Matthew W Davis
Journal of Clinical Pharmacology|February 8, 2002
Comparison of the pharmacokinetics of oxycodone administered in three Percocet formulationsArnold R Gammaitoni, Matthew W Davis
The Annals of Pharmacotherapy|February 19, 2002
Pharmacokinetics and tolerability of lidocaine patch 5% with extended dosingArnold R Gammaitoni, Matthew W Davis
Cutis|March 13, 2003
Improving patient satisfaction and acne severity in patients with mild to moderate acne: the BEST studyJonathan Weiss, Joel Shavin, Matthew W Davis
Cutis|March 13, 2003
Overall results of the BEST study following treatment of patients with mild to moderate acneJonathan Weiss, Joel Shavin, Matthew W Davis
The Consultant Pharmacist : the Journal of the American Society of Consultant Pharmacists|March 7, 2013
Colchicine-antimicrobial drug interactions: what pharmacists need to know in treating goutMatthew W Davis, Suman Wason, Jennifer L Digiacinto
Clinical Therapeutics|June 28, 2011
Single-dose bioequivalence of 105-mg fenofibric acid tablets versus 145-mg fenofibrate tablets under fasting and fed conditions: a report of two phase I, open-label, single-dose, randomized, crossover clinical trialsAnthony R Godfrey, Jennifer Digiacinto, Matthew W Davis
Pageof 4